NASDAQ:RETA Reata Pharmaceuticals (RETA) Stock Forecast, Price & News $89.14 -0.56 (-0.62%) (As of 03:10 PM ET) Add Compare Share Share Today's Range$87.82▼$90.9850-Day Range$79.22▼$105.3752-Week Range$18.47▼$106.69Volume335,781 shsAverage Volume1.22 million shsMarket Capitalization$3.35 billionP/E RatioN/ADividend YieldN/APrice Target$99.89 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Reata Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside12.5% Upside$99.89 Price TargetShort InterestBearish17.62% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.21Based on 6 Articles This WeekInsider TradingSelling Shares$12.19 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($10.31) to ($4.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector423rd out of 1,006 stocksPharmaceutical Preparations Industry200th out of 492 stocks 2.4 Analyst's Opinion Consensus RatingReata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $99.89, Reata Pharmaceuticals has a forecasted upside of 12.5% from its current price of $88.82.Amount of Analyst CoverageReata Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted17.62% of the float of Reata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReata Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reata Pharmaceuticals has recently increased by 6.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReata Pharmaceuticals does not currently pay a dividend.Dividend GrowthReata Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReata Pharmaceuticals has received a 78.64% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Reata Pharmaceuticals is -0.75. Previous Next 2.3 News and Social Media Coverage News SentimentReata Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Reata Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for RETA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Reata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reata Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,190,275.00 in company stock.Percentage Held by Insiders28.70% of the stock of Reata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.13% of the stock of Reata Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reata Pharmaceuticals are expected to grow in the coming year, from ($10.31) to ($4.37) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Reata Pharmaceuticals (NASDAQ:RETA) StockReata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.Read More Receive RETA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RETA Stock News HeadlinesMay 30, 2023 | markets.businessinsider.comReata Pharmaceuticals (RETA) Gets a Buy from Goldman SachsMay 29, 2023 | benzinga.comRETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.May 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 25, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Reata Pharmaceuticals (RETA)May 24, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Reata Pharmaceuticals (RETA)May 23, 2023 | seekingalpha.comReata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone Discontinuation (Rating Upgrade)May 22, 2023 | americanbankingnews.comReata Pharmaceuticals (NASDAQ:RETA) Coverage Initiated by Analysts at StockNews.comMay 22, 2023 | americanbankingnews.comReata Pharmaceuticals (NASDAQ:RETA) versus China Health Industries (OTCMKTS:CHHE) Head-To-Head ComparisonMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 20, 2023 | americanbankingnews.comMichael D. Wortley Sells 894 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) StockMay 20, 2023 | americanbankingnews.comManmeet Singh Soni Sells 21,507 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) StockMay 19, 2023 | americanbankingnews.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Receives $99.89 Consensus Target Price from AnalystsMay 18, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Buy Rating on Reata Pharmaceuticals (RETA)May 18, 2023 | americanbankingnews.comInsider Selling: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) SVP Sells 6,750 Shares of StockMay 15, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Their Buy Rating for Reata Pharmaceuticals (RETA)May 13, 2023 | americanbankingnews.comCantor Fitzgerald Trims Reata Pharmaceuticals (NASDAQ:RETA) Target Price to $110.00May 13, 2023 | americanbankingnews.comReata Pharmaceuticals (NASDAQ:RETA) PT Raised to $104.00 at LADENBURG THALM/SH SHMay 13, 2023 | americanbankingnews.comBarclays Boosts Reata Pharmaceuticals (NASDAQ:RETA) Price Target to $98.00May 12, 2023 | msn.comBarclays Maintains Reata Pharmaceuticals Inc - (RETA) Overweight RecommendationMay 12, 2023 | americanbankingnews.comReata Pharmaceuticals (NASDAQ:RETA) Shares Gap Down Following Analyst DowngradeMay 12, 2023 | marketwatch.com8-K: REATA PHARMACEUTICALS INCMay 12, 2023 | msn.comRecap: Reata Pharmaceuticals Q1 EarningsMay 11, 2023 | msn.comUnusual Put Option Trade in Reata Pharmaceuticals Inc - (RETA) Worth $1,125.00KMay 10, 2023 | msn.comReata sheds 18% after halting kidney disease programsMay 10, 2023 | seekingalpha.comReata Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 9, 2023 | msn.comReata Pharmaceuticals Q1 2023 Earnings PreviewMay 9, 2023 | msn.comEarnings Outlook For Reata PharmaceuticalsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RETA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RETA Company Calendar Last Earnings5/10/2023Today5/31/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RETA CUSIPN/A CIK1358762 Webwww.reatapharma.com Phone(972) 865-2219FaxN/AEmployees346Year Founded2002Price Target and Rating Average Stock Price Forecast$99.89 High Stock Price Forecast$120.00 Low Stock Price Forecast$75.00 Forecasted Upside/Downside+13.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,900,000.00 Net Margins-9,897.91% Pretax Margin-23,662.79% Return on Equity-922.50% Return on Assets-64.89% Debt Debt-to-Equity RatioN/A Current Ratio6.09 Quick Ratio6.09 Sales & Book Value Annual Sales$2.22 million Price / Sales1,491.85 Cash FlowN/A Price / Cash FlowN/A Book Value($3.48) per share Price / Book-25.34Miscellaneous Outstanding Shares37,550,000Free Float26,774,000Market Cap$3.31 billion OptionableOptionable Beta1.53 Social Links Key ExecutivesJ. Warren HuffChairman & Chief Executive OfficerManmeet Singh SoniPresident, Chief Operating & Financial OfficerW. Christian WigleyChief Scientific Officer & Senior Vice PresidentSamina KhanChief Medical Officer & Senior Vice PresidentDakota GallivanVP, Chief Healthcare & Compliance OfficerKey CompetitorsProthenaNASDAQ:PRTABlueprint MedicinesNASDAQ:BPMCUltragenyx PharmaceuticalNASDAQ:RAREArrowhead PharmaceuticalsNASDAQ:ARWRAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 703 shares on 5/26/2023Ownership: 0.015%Ameriprise Financial Inc.Sold 3,641 shares on 5/22/2023Ownership: 0.014%New York State Common Retirement FundSold 5,307 shares on 5/18/2023Ownership: 0.040%Thrivent Financial for LutheransSold 66,555 shares on 5/17/2023Ownership: 0.019%Belpointe Asset Management LLCBought 219 shares on 5/16/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions RETA Stock - Frequently Asked Questions Should I buy or sell Reata Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RETA shares. View RETA analyst ratings or view top-rated stocks. What is Reata Pharmaceuticals' stock price forecast for 2023? 7 equities research analysts have issued twelve-month target prices for Reata Pharmaceuticals' shares. Their RETA share price forecasts range from $75.00 to $120.00. On average, they predict the company's share price to reach $99.89 in the next year. This suggests a possible upside of 13.3% from the stock's current price. View analysts price targets for RETA or view top-rated stocks among Wall Street analysts. How have RETA shares performed in 2023? Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 132.2% and is now trading at $88.20. View the best growth stocks for 2023 here. When is Reata Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our RETA earnings forecast. How were Reata Pharmaceuticals' earnings last quarter? Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($3.14) earnings per share for the quarter, missing analysts' consensus estimates of ($2.34) by $0.80. The company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.73 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 922.50% and a negative net margin of 9,897.91%. What ETFs hold Reata Pharmaceuticals' stock? ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO? 10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Reata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC). When did Reata Pharmaceuticals IPO? (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO. What is Reata Pharmaceuticals' stock symbol? Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA." Who are Reata Pharmaceuticals' major shareholders? Reata Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.02%), Perceptive Advisors LLC (5.91%), First Light Asset Management LLC (4.32%), Deutsche Bank AG (4.07%), Wellington Management Group LLP (3.87%) and State Street Corp (1.72%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff. View institutional ownership trends. How do I buy shares of Reata Pharmaceuticals? Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reata Pharmaceuticals' stock price today? One share of RETA stock can currently be purchased for approximately $88.20. How much money does Reata Pharmaceuticals make? Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $3.31 billion and generates $2.22 million in revenue each year. How many employees does Reata Pharmaceuticals have? The company employs 346 workers across the globe. How can I contact Reata Pharmaceuticals? Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com. This page (NASDAQ:RETA) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.